Spindle cell lesions of the breast

Share :
Published: 1 Feb 2023
Views: 656
Rating:
Save
Prof Cecily Quinn - St Vincent’s University Hospital, Dublin, Ireland

Prof Cecily Quinn speaks to ecancer at BGICC 2023 about spindle cell lesions of the breast.

She explains the different classifications of spindle cell lesions and approaches to diagnosis.

Prof Quinn concludes by highlighting the importance of molecular studies for diagnosis in today's world of pathology.

I would like to talk a little about the lecture I gave yesterday on spindle cell lesions of the breast at the BGICC 2023 meeting in Cairo, Egypt. Spindle cell lesions of the breast are challenging lesions for the pathologist. Any soft tissue spindle cell lesion may occur in the breast; these are obviously less common than epithelial lesions. The problem with soft-tissue lesions in the breast is that the morphology can be very confusing; benign lesions may look malignant and malignant lesions may look benign. 

I spoke about the classification of these lesions and an approach to diagnosis. A modern approach to classification is to regard these lesions as bland-appearing lesions or malignant-appearing lesions. The advantage of this approach to classification on H&E microscopy is that it encourages us to consider a malignant diagnosis when looking at a bland-appearing lesion and a benign diagnosis which may occur in a malignant-appearing lesion. 

I went on then to discuss the differential diagnosis of these two main categories. I like to consider these really in groups of three. So, taking the bland-appearing lesions first of all we can consider bland-appearing lesions as those that have an irregular outline and this differential diagnosis includes primarily fibromatosis-like and metaplastic carcinoma. That is the diagnosis that we do not want to miss in considering these lesions. Other differential diagnoses include fibromatosis, nodular fasciitis, pseudoangiomatous stromal hyperplasia and low-grade angiosarcoma. 

The second category of bland-appearing lesions we can consider is those that have a round configuration; these include myofibroblastoma, leiomyoma, neural tumours and hamartoma. They are the two main categories, then, of bland-appearing lesions and that approach is useful because it tends to immediately give rise to a set of differential diagnoses.

Malignant-appearing lesions, then, broadly speaking, our main differential diagnosis there is metaplastic spindle cell carcinoma; that is our top differential diagnosis. Other differential diagnoses include malignant phyllodes tumour, sarcoma, myoepithelial tumours and then the benign lesions which can look malignant, in particular nodular fasciitis and granulation tissue with scar formation. 

So when we look at these lesions on a needle core biopsy, we try to take account, first of all, all of the information that is available to us. It is very important that we remember to interpret any pathological findings in context. So we take account of the clinical findings, the radiological findings and, in particular, any relevant past medical history that the patient may have. So our first line, then, when we have considered all that information, to examine our H&E section and to look at the spindle cell proliferation itself – is it pure, is it mixed? If it’s a mixed proliferation usually the diagnosis is easier and more apparent. Then we look at the configuration of the lesions, the growth pattern, the presence or absence of necrosis and any particular clues such as pigment position or calcification that may help us to narrow down our differential diagnosis.

Having considered the H&E then, our next line, really, is consideration of immunohistochemistry. There is a large number of immunohistochemical stains at our disposal; the one that we really most commonly use is cytokeratin. It is important when using cytokeratin to use a panel of antibodies as staining in metaplastic carcinoma can be focal or even absent. If we find this on a needle core biopsy we should repeat those stains on excision. Other useful stains are beta catenin for the diagnosis of fibromatosis, but we have to be careful because sometimes we can get non-specific staining in a metaplastic carcinoma. Other useful stains are CD34 and p63. 

In today’s world of pathology, molecular studies are becoming increasingly important in diagnosis and there are specific mutations in a number of conditions, such as fibromatosis, nodular fasciitis and in many different types of sarcoma, that may help us to make a more precise diagnosis.


 

Related Videos

ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer

Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer ( Prof Karim Fizazi, Dr Anders Bjartell, Dr Niven Mehra and Prof Eleni Efstathiou )
19 Sep 2024

Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC

Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force
Potential benefit to response rates from trastuzumab added to perioperative chemotherapy for patients with HER-2+ GC ( Dr Anna Wagner - The University of Lausanne, Lausanne, Switzerland, Co-chair of the EORTC Gastric Cancer Task Force )
6 Jul 2023

First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer

Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA
First-line NALIRIFOX shows improvement in OS and PFS in metastatic pancreatic cancer ( Prof Eileen M O’Reilly - Memorial Sloan Kettering Cancer Center, New York City, USA )
15 Jun 2023

SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer

Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
SOFT study: Clinical relevance of genomic alterations in premenopausal HR+, HER2- early breast cancer ( Prof Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
28 Mar 2023

Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer

Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany
Diagnostic performance of 18F-rhPSMA-7.3 PET in newly diagnosed unfavourable intermediate to very high-risk prostate cancer ( Prof Tobias Maurer - Martini-Klinik Prostate Cancer Center, Hamburg, Germany )
16 Mar 2023

IORT at the Asian Hospital and Medical Center

Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines
IORT at the Asian Hospital and Medical Center ( Dr Aldine Basa - Asian Hospital and Medical Center, Manila, Philippines )
9 Mar 2023

The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival

Dr Jayant Vaidya - University College London, London, UK
The TARGIT-A randomised trial: TARGIT-IORT versus whole breast radiation therapy: long-term local control and survival ( Dr Jayant Vaidya - University College London, London, UK )
9 Mar 2023

Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer

Dr Jayant Vaidya - University College London, London, UK
Insights from TARGIT-A trial of targeted IORT during lumpectomy for breast cancer ( Dr Jayant Vaidya - University College London, London, UK )
9 Mar 2023

Surgical management of Axilla: Past, present and future

Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA
Surgical management of Axilla: Past, present and future ( Prof Terry Mamounas - Orlando Health Cancer Institute, Orlando, USA )
1 Feb 2023